The FDA cleared Tandem’s Control-IQ+ automated insulin delivery algorithm for people with type 2 diabetes.

Control IQ+ builds on the company’s proven Control-IQ algorithm. It also includes enhancements to accommodate input of expanded weight and total daily insulin ranges. Tandem expects to make Control IQ+ available for new and existing customers in the U.S. in March 2025.

San Diego-based Tandem now joins Insulet in offering AID technology for the type 2 population